Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

NCT07037277 is registered in ClinicalTrials.gov with Atea Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07037277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07037277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study
Lead sponsor
Atea Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 2, 2025
Completion date
March 31, 2027
Enrollment
880 (estimated)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hepatitis c virus chronic infection, hepatitis c virus infection, hepatitis c, chronic